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OLIGONUCLEOTIDE COMPOUND AND 
METHOD FOR TREATING NIDOVIRUS 
INFECTIONS 
This application is a divisional of US. application Ser. No. 
11/432,155 ?led May 10, 2006, now abandoned, which is a 
continuation-in-part of US. application Ser. No. 11/022,358 
?led Dec. 22, 2004, now abandoned, which claims the bene?t 
ofpriority ofU.S. Application No. 60/532,701 ?led Dec. 24, 
2003, now abandoned. All applications are incorporated in 
their entirety herein by reference. 
A portion of the work described herein was supported by 
grant numbers NS 41219, Al 43103, Al 25913 from the 
National Institutes of Health, and HHSN266200400058C 
from Health and Human Services, The United States Govem 
ment has certain rights in this invention. 
FIELD OF THE INVENTION 
This invention relates to an oligonucleotide analog for use 
in treating in animals a coronavirus infection or, more gener 
ally, an infection by a member of the Nidovirales order, to an 
antiviral method employing the analog, and to a method for 
monitoring binding of the analog to a viral genome target site. 
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BACKGROUND OF THE INVENTION 
The Nidovirales is a recently established order comprising 
the families Arteriviridae (genus Arterivirus) and Coronaviri 
dae (genera Coronavirus and Torovirus). Despite noteworthy 
differences in genome size, complexity and virion architec 
ture, coronaviruses, toroviruses and arteriviruses are remark 
ably similar in genome organization and replication strategy 
(de Vries, Horzinek et al 1997). The name Nidovirales is 
derived from the Latin nidus, to nest, and refers to the 3' 
coterminal nested set of subgenomic (sg) viral mRNAs pro 
duced during infection. Sequence comparisons of the repli 
case genes suggest that the Nidovirales have evolved from a 
common ancestor despite their substantial differences. 
Coronaviruses cause about 30% of common colds in 
humans and, unlike rhinoviruses, cause both upper and lower 
respiratory infections, the latter being a more serious af?ic 
tion. In addition, coronaviruses cause gastroenteritis and diar 
rhea in humans and many other serious diseases in non 
human animals including mice, chickens, pigs and cats. 
Although no known human arteriviruses exist, arteriviruses 
cause a number of diseases in horses, pigs, mice and mon 
keys. 
The most well-known human coronavirus has only 
recently appeared and is responsible for severe acute respira 
tory syndrome (SARS), a life threatening form of pneumonia 
(Peiris, Yuen et al 2003). SARS is caused by a previously 
unknown coronavirus named SARS coronavirus (SARS 
CoV). First appearing in November 2002, an epidemic 
emerged that spread from its zoonotic origin in Guangdong 
Province, China, to 26 countries on ?ve continents. By 
August 2003, a cumulative total of 8422 cases and 774 deaths 
had been recorded by the World Health Organization. The 
rapid transmission by aerosols and the fecal-oral route and the 
high mortality rate (11%) make SARS a potential global 
threat for which no ef?cacious therapy is available. 
No vaccines for coronaviruses or arteriviruses (Nidovi 
ruses) are available and no effective antiviral therapies are 
available to treat an infection. As with many other human 
viral pathogens, available treatment involves supportive mea 
sures such as anti-pyretics to keep fever down, ?uids, antibi 
otics for secondary bacterial infections and respiratory sup 
port as necessary. 
In view of the severity of the diseases caused by Nidovi 
ruses and the lack of effective prevention or therapies, it is 
therefore an object of the present invention to provide thera 
peutic compounds and methods for treating a host infected 
with a coronavirus, torovirus or arterivirus. 
SUMMARY OF THE INVENTION 
In one aspect, the invention includes an oligonucleotide 
compound for use in inhibiting replication of a nidovirus in 
human cells. The compound is characterized by: (i) a 
nuclease-resistant backbone, (ii) capable of uptake by virus 
infected human cells, (iii) containing between 8-25 nucle 
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otide bases, and (iv) having a sequence that is complementary 
to at least 8 bases contained in one of: 
(1) a sequence in a 5' leader sequence of the nidovirus’ 
positive-strand genomic RNA from the group SEQ ID NOS: 
1-9, each sequence of which includes an internal leader tran 
scriptional regulatory sequence; and, 
(2) a sequence in a negative-strand 3' subgenomic region of 
the virus from the group exempli?ed by SEQ ID NOS: 10-19, 
each sequence of which includes an internal body transcrip 
tional regulatory sequence that is substantially complemen 
tary to the corresponding leader transcriptional regulatory 
sequence. 
The compound is capable of forming with the nidovirus (1) 
positive-strand genomic RNA or (2) the negative-strand 3' 
sub genomic region, a heteroduplex structure characterized by 
(1) a Tm of dissociation of at least 45° C., and (2) a disrupted 
base pairing between the transcriptional regulatory sequences 
in the 5' leader region of the positive-strand viral genome and 
negative-strand 3' subgenomic region. 
The compound may be composed of morpholino subunits 
and phosphorus-containing intersubunit linkages joining a 
morpholino nitrogen of one subunit to a 5' exocyclic carbon of 
an adjacent subunit. Exemplary intersubunit linkages are 
phosphorodiamidate linkages in accordance with the struc 
ture: 
Y1 
‘ :Oj/ Pj 
T 
where Y1:O, Z:O, Pj is a purine or pyrimidine base 
pairing moiety effective to bind, by base-speci?c hydrogen 
bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, 
thioalkoxy, amino or alkyl amino, including dialkylamino. 
In one general embodiment, the compound has a sequence 
complementary to at least 8 bases contained in the 5' leader 
sequence of the nidovirus’ positive-strand genomic RNA 
from the group SEQ ID NOS: 1-9. The compound sequence is 
preferably complementary to at least a portion of the tran 
scriptional regulatory sequence contained within one of the 
sequences SEQ ID NOS: 1-9. Exemplary compound 
sequences in this embodiment include SEQ ID NOS: 20-35. 
The compound may be composed of morpholino subunits 
linked with the uncharged linkages described above inter 
spersed with linkages that are positively charged at physi 
ological pH. The total number of positively charged linkages 
is between 2 and no more than half of the total number of 
linkages. The positively charged linkages may have the struc 
ture above, where X is 1-piperazine. 
For use in inhibiting replication of human SARS virus, the 
compound may contain one of sequences SEQ ID NOS: 26 
and 27. For use in inhibiting replication of human coronavius 
229E or human coronavirus-OC43, the compound may con 
tain one of the sequences SEQ ID NOS: 22 or 23, for the 
coronavirus-229E, and the sequence SEQ ID NOS: 24 or 25, 
for the coronavirus-OC43. For use in inhibiting replication of 
feline coronavirus, the compound may contain SEQ ID NOS: 
20 or 21. 
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In another general embodiment, the compound has a 
sequence complementary to at least 8 bases contained in the 
negative-strand 3' sub genomic region of the virus exempli?ed 
by the group SEQ ID NOS: 10-19. The compound preferably 
has a sequence complementary to at least a portion of the 
minus-strand body transcriptional regulatory sequence con 
tained within one of the sequences SEQ ID NOS: 10-19. 
Exemplary compound sequences in this embodiment contain 
a sequence from the group SEQ ID NOS: 36-45. 
For use in inhibiting replication of human SARS virus, the 
compound may contain one of the sequences SEQ ID NOS: 
3 6-43. For use in inhibiting replication of simian hemorrhagic 
fever virus, the compound may contain the SEQ ID NOS: 44 
and 45. 
In the method of the invention for inhibiting nidovirus 
replication in virus-infected cells, the cells are exposed to the 
oligonucleotide compound, in an amount suf?cient to inhibit 
nidovirus replication in the virus-infected cells. The inhibi 
tion is due to base-pair binding of the compound to (l) a 
sequence in a 5' leader sequence of the nidovirus’ positive 
strand genomic RNA that includes an internal leader tran 
scriptional regulatory sequence, or (2) a sequence in a nega 
tive-strand 3' subgenomic region of the virus that includes an 
internal body transcriptional regulatory sequence that is sub 
stantially complementary to the corresponding transcrip 
tional regulatory sequence contained the 5' leader sequence. 
This base-pair binding forms a viral-RNA/compound hetero 
duplex characterized by (l) a Tm of dissociation of at least 45° 
C., and (2) a disrupted base pairing between the transcrip 
tional regulatory sequences in the 5' leader region of the 
positive-strand viral genome and negative-strand 3' subge 
nomic region. Various embodiments of the compound, noted 
above, are incorporated into the method. 
For use in treating a nidovirus infection in a human or 
veterinary-animal subject, the compound may be adminis 
tered orally to the subject, to contact the compound with the 
virus-infected cells. The method may further include moni 
toring a subject body ?uid for the appearance of a heterodu 
plex composed of the oligonucleotide compound and a 
complementary portion of the viral genome in positive- or 
negative-strand form. 
These and other objects and features of the invention will 
become more fully apparent when the following detailed 
description of the invention is read in conjunction with the 
accompanying drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a genetic map and predicted viral proteins of 
the SARS coronavirus which is representative of the genome 
organization of all Nidoviruses. Also shown are the eight 
subgenomic mRNAs (mRNA 2-8) that are produced. The 
small black boxes at the 5' end of the genomic and subge 
nomic RNAs represent the common 72 nucleotide leader 
RNA sequence derived from the 5' terminal 72 nucleotides of 
the genomic RNA during discontinuous transcription. 
FIG. 2A-2B is a schematic representation of Nidovirus 
RNA replication and the process of discontinuous transcrip 
tion that results in a nested set of 3'co-terminal subgenomic 
mRNAs with a common 5' leader sequence. FIG. 2B indicates 
the point at which antisense oligomers targeted to the 5' 
positive-strand leader transcriptional regulatory sequence 
interfere with this process. Also shown in FIG. 2B is an 
antisense oligomer targeted to the 3' minus-strand body tran 
scriptional regulatory sequence. 
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FIG. 3A-3G show the backbone structures of various oli 
gonucleotide analogs with uncharged backbones and FIG. 3H 
shows a preferred cationic linkage. 
FIGS. 4A-4D show the repeating subunit segment of exem 
plary morpholino oligonucleotides, designated 3A-3D. 
FIG. 5 shows graphically the reduction of SARS viral titer 
when SARS-infected cells are cultured in the presence of 
either of two antisense PMOs targeted at the leader transcrip 
tional regulatory sequence. 
FIG. 6 shows graphically the reduction in SARS plaque 
size when infected cells are cultured in the presence of either 
of two antisense PMOs targeted at the leader transcriptional 
regulatory sequence. 
FIGS. 7A and 7B show photomicrographs of SARS-in 
fected cells, control cells and the corresponding SARS-in 
duced cytopathic effects in the presence of a variety of anti 
sense PMO compounds including two antisense PMOs 
targeted at the leader transcriptional regulatory sequence. 
FIGS. 8A-8C show photomicrographs of EAV-infected 
cells, control cells and the corresponding immuno?uores 
cence using labeled antibodies to EAV-speci?c proteins in the 
presence of an antisense PMO that targets the leader TRS of 
EAV. 
FIG. 9 shows graphically the reduction of MHV viral titer 
when MHV-infected cells are cultured in the presence of a 
PMO targeted to the leader TRS of MHV. 
FIG. 10 shows the synthetic steps to produce subunits used 
to produce +PMO containing the (l -piperazino) phosphi 
nylideneoxy cationic linkage as shown in FIG. 3H. 
DETAILED DESCRIPTION OF THE INVENTION 
I. De?nitions 
The terms below, as used herein, have the following mean 
ings, unless indicated otherwise: 
The terms “oligonucleotide analog” refers to oligonucle 
otide having (i) a modi?ed backbone structure, e.g., a back 
bone other than the standard pho sphodiester linkage found in 
natural oligo- and polynucleotides, and (ii) optionally, modi 
?ed sugar moieties, e.g., morpholino moieties rather than 
ribose or deoxyribose moieties. The analog supports bases 
capable of hydrogen bonding by Watson-Crick base pairing 
to standard polynucleotide bases, where the analog backbone 
presents the bases in a manner to permit such hydrogen bond 
ing in a sequence-speci?c fashion between the oligonucle 
otide analog molecule and bases in a standard polynucleotide 
(e.g., single-stranded RNA or single-stranded DNA). Pre 
ferred analogs are those having a substantially uncharged, 
phosphorus containing backbone. 
A substantially uncharged, phosphorus containing back 
bone in an oligonucleotide analog is one in which a majority 
of the subunit linkages, e.g., between 50-100%, are 
uncharged at physiological pH, and contain a single phospho 
rous atom. The analog contains between 8 and 40 subunits, 
typically about 8-25 subunits, and preferably about 12 to 25 
subunits. The analog may have exact sequence complemen 
tarity to the target sequence or near complementarity, as 
de?ned below. 
A “subunit” of an oligonucleotide analog refers to one 
nucleotide (or nucleotide analog) unit of the analog. The term 
may refer to the nucleotide unit with or without the attached 
intersubunit linkage, although, when referring to a “charged 
subunit”, the charge typically resides within the intersubunit 
linkage (e.g. a phosphate or phosphorothioate linkage). 
A “morpholino oligonucleotide analog” is an oligonucle 
otide analog composed of morpholino subunit structures of 
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the form shown in FIGS. 3A-3D, where (i) the structures are 
linked together by phosphorus-containing linkages, one to 
three atoms long, joining the morpholino nitrogen of one 
subunit to the 5' exocyclic carbon of an adjacent subunit, and 
(ii) PI. and P]. are purine or pyrimidine base-pairing moieties 
effective to bind, by base-speci?c hydrogen bonding, to a 
base in a polynucleotide. The purine or pyrimidine base 
pairing moiety is typically adenine, cytosine, guanine, uracil 
or thymine. The synthesis, structures, and binding character 
istics of morpholino oligomers are detailed in US. Pat. Nos. 
5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 
5,521,063, and 5,506,337, all of which are incorporated 
herein by reference. 
The subunit and linkage shown in FIG. 3B are used for 
six-atom repeating-unit backbones, as shown in FIG. 3B 
(where the six atoms include: a morpholino nitrogen, the 
connected phosphorus atom, the atom (usually oxygen) link 
ing the phosphorus atom to the 5' exocyclic carbon, the 5' 
exocyclic carbon, and two carbon atoms of the next mor 
pholino ring). In these structures, the atom Yl linking the 5' 
exocyclic morpholino carbon to the phosphorus group may be 
sulfur, nitrogen, carbon or, preferably, oxygen. The X moiety 
pendant from the phosphorus is any stable group which does 
not interfere with base-speci?c hydrogen bonding. Preferred 
X groups include ?uoro, alkyl, alkoxy, thioalkoxy, and alkyl 
amino, including cyclic amines, all of which can be variously 
substituted, as long as base-speci?c bonding is not disrupted. 
Alkyl, alkoxy and thioalkoxy preferably include 1-6 carbon 
atoms. Alkyl amino preferably refers to lower alkyl (C 1 to C6) 
substitution, and cyclic amines are preferably 5- to 7-mem 
bered nitrogen heterocycles optionally containing 1-2 addi 
tional heteroatoms selected from oxygen, nitrogen, and sul 
fur. Z is sulfur or oxygen, and is preferably oxygen. 
A preferred morpholino oligomer is a phosphorodiami 
date-linked morpholino oligomer, referred to herein as a 
PMO. Such oligomers are composed of morpholino subunit 
structures such as shown in FIG. 2B, where X:NH2, NHR, 
or NR2 (where R is lower alkyl, preferably methyl), Y:O, 
and Z:O, and Pi and Pj are purine or pyrimidine base 
pairing moieties effective to bind, by base-speci?c hydrogen 
bonding, to a base in a polynucleotide, as seen in FIG. 3G. 
Also preferred are morpholino oligomers where the pho spho 
rdiamidate linkages are uncharged linkages as shown in FIG. 
3G interspersed with cationic linkages as shown in FIG. 3H 
where, in FIG. 2B, X:1-piperazino. In another FIG. 2B 
embodiment, XIlower alkoxy, such as methoxy or ethoxy, 
Y:NH or NR, where R is lower alkyl, and Z:O. 
The term “substituted”, particularly with respect to an 
alkyl, alkoxy, thioalkoxy, or alkylamino group, refers to 
replacement of a hydrogen atom on carbon with a heteroa 
tom-containing substituent, such as, for example, halogen, 
hydroxy, alkoxy, thiol, alkylthio, amino, alkylamino, imino, 
oxo (keto), nitro, cyano, or various acids or esters such as 
carboxylic, sulfonic, or phosphonic. It may also refer to 
replacement of a hydrogen atom on a heteroatom (such as an 
amine hydrogen) with an alkyl, carbonyl or other carbon 
containing group. 
As used herein, the term “target”, relative to the viral 
genomic RNA, refers to a viral genomic RNA, and may 
include either the positive strand RNA which is the replicative 
strand of the virus, or the negative or antisense strand which 
is formed in producing multiple new copies of the positive 
strand RNA. 
The term “target sequence” refers to a portion of the target 
RNA against which the oligonucleotide analog is directed, 
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that is, the sequence to which the oligonucleotide analog will 
hybridize. The target sequence includes at least a portion of 
one of the sequences identi?ed as SEQ ID NOS: 1-9, repre 
senting the genome’s leader transcriptional regulatory 
sequence in a member of the Nidovirales, as discussed further 
below. Another target sequence includes at least a portion of 
the 3' minus-strand body transcriptional regulatory sequence 
exempli?ed by SEQ ID NOS: 10-19. 
The term “targeting sequence” is the sequence in the oli 
gonucleotide analog that is complementary or substantially 
complementary to the target sequence in the RNA genome. 
The entire sequence, or only a portion of, the analog may be 
complementary to the target sequence, or only a portion of the 
total analog sequence. For example, in an analog having 20 
bases, only 8-12 may be targeting sequences. Typically, the 
targeting sequence is formed of contiguous bases in the ana 
log, but may alternatively be formed of non-contiguous 
sequences that whenplaced together, e.g., from opposite ends 
of the analog, constitute sequence that spans the target 
sequence. As will be seen, the target and targeting sequences 
are selected such that binding of the analog to part of the viral 
genome acts to disrupt or prevent formation of subgenomic 
RNA formed by the interaction between leader and body 
transcriptional regulatory sequences. 
Target and targeting sequences are described as “comple 
mentary” to one another when hybridization occurs in an 
antiparallel con?guration. A double-stranded polynucleotide 
can be “complementary” to another polynucleotide. A target 
ing sequence may have “near” or “substantial” complemen 
tarity to the target sequence and still function for the purpose 
of the present invention. Preferably, the oligonucleotide ana 
logs employed in the present invention have at most one 
mismatch with the target sequence out of 10 nucleotides, and 
preferably at mo st one mismatch out of 20. Alternatively, the 
antisense oligomers employed have at least 90% sequence 
homology, and preferably at least 95% sequence homology, 
with the exemplary targeting sequences as designated herein. 
An oligonucleotide analog “speci?cally hybridizes” to a 
target polynucleotide if the oligomer hybridizes to the target 
under physiological conditions, with a Tm substantially 
greater than 45° C., preferably at least 50° C., and typically 
60° C.-80° C. or higher. Such hybridization preferably corre 
sponds to stringent hybridization conditions. At a given ionic 
strength and pH, the Tm is the temperature at which 50% of a 
target sequence hybridizes to a complementary polynucle 
otide. Again, such hybridization may occur with “near” or 
“substantial” complementary of the antisense oligomer to the 
target sequence, as well as with exact complementarity. 
A “nuclease-resistant” oligomeric molecule (oligomer) 
refers to one whose backbone is substantially resistant to 
nuclease cleavage, in non-hybridized or hybridized form; by 
common extracellular and intracellular nucleases in the body; 
that is, the oligomer shows little or no nuclease cleavage 
under normal nuclease conditions in the body to which the 
oligomer is exposed. 
A “heteroduplex” refers to a duplex between an oligoncu 
leotide analog and the complementary portion of a target 
RNA. A “nuclease-resistant heteroduplex” refers to a hetero 
duplex formed by the binding of an antisense oligomer to its 
complementary target, such that the heteroduplex is substan 
tially resistant to in vivo degradation by intracellular and 
extracellular nucleases, such as RNAseH, which are capable 
of cutting double-stranded RNA/RNA or RNA/DNA com 
plexes. 
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A “base-speci?c intracellular binding event involving a 
target RN ” refers to the speci?c binding of an oligonucle 
otide analog to a target RNA sequence inside a cell. The base 
speci?city of such binding is sequence speci?c. For example, 
a single-stranded polynucleotide can speci?cally bind to a 
single-stranded polynucleotide that is complementary in 
sequence. 
An “effective amount” of an antisense oligomer, targeted 
against an infecting ssRNA virus, is an amount effective to 
reduce the rate of replication of the infecting virus, and/or 
viral load, and/or symptoms associated with the viral infec 
tion. 
As used herein, the term “body ?uid” encompasses a vari 
ety of sample types obtained from a subject including, urine, 
saliva, plasma, blood, spinal ?uid, or other sample of biologi 
cal origin, such as skin cells or dermal debris, and may refer 
to cells or cell fragments suspended therein, or the liquid 
medium and its solutes. 
The term “relative amount” is used where a comparison is 
made between a test measurement and a control measure 
ment. The relative amount of a reagent forming a complex in 
a reaction is the amount reacting with a test specimen, com 
pared with the amount reacting with a control specimen. The 
control specimen may be run separately in the same assay, or 
it may be part of the same sample (for example, normal tissue 
surrounding a malignant area in a tissue section). 
“Treatment” of an individual or a cell is any type of inter 
vention provided as a means to alter the natural course of the 
individual or cell. Treatment includes, but is not limited to, 
administration of e. g., a pharmaceutical composition, and 
may be performed either prophylactically, or subsequent to 
the initiation of a pathologic event or contact with an etiologic 
agent. The related term “improved therapeutic outcome” rela 
tive to a patient diagnosed as infected with a particular virus, 
refers to a slowing or diminution in the growth of virus, or 
viral load, or detectable symptoms associated with infection 
by that particular virus. 
An agent is “actively taken up by mammalian cells” when 
the agent can enter the cell by a mechanism other than passive 
diffusion across the cell membrane. The agent may be trans 
ported, for example, by “active transport”, referring to trans 
port of agents across a mammalian cell membrane by e.g. an 
ATP-dependent transport mechanism, or by “facilitated 
transport”, referring to transport of antisense agents across 
the cell membrane by a transport mechanism that requires 
binding of the agent to a transport protein, which then facili 
tates passage of the bound agent across the membrane. For 
both active and facilitated transport, the oligonucleotide ana 
log preferably has a substantially uncharged backbone, as 
de?ned below. Alternatively, the antisense compound may be 
formulated in a complexed form, such as an agent having an 
anionic backbone complexed with cationic lipids or lipo 
somes, which can be taken into cells by an endocytotic 
mechanism. The analog may be conjugated, e.g., at its 5' or 3' 
end, to an arginine rich peptide, e.g., the HIV TAT protein, or 
polyarginine, to facilitate transport into the target host cell. 
The term “coronavirus” is used herein to include all mem 
bers of the Coronaviridae family including viruses of the 
Coronavirus and Torovirus genera. The term “arterivirus” 
includes members of the Arteriviridae family which includes 
the Arterivirus genera. The term “Nidovirus” refers to viruses 
of the Nidovirales order which includes the families Coro 
naviridae and Arteriviridae. Representative Nidoviruses are 
listed in Table 1. below. 
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TABLE 1 
Representative Nidoviruses 
Virus Name Abbreviation 
Canine coronavirus CCoV 
Feline coronavirus FCoV 
Human coronavirus 229E HCoV—229E 
Porcine epidemic diarrhea virus PEDV 
Transmissible gastroenteritis virus TGEV 
Porcine Respiratory Coronavirus PRCV 
Bovine coronavirus BCoV 
Human coronavirus OC43 HCoV—OC43 
Murine hepatitis virus MHV 
Rat coronavirus RCV 
Infectious bronchitis virus IBV 
Turkey coronavirus TCoV 
Rabbit coronavirus RbCoV 
SARS coronavirus SARS—CoV 
Human torovirus HuTV 
Equine arteritis virus EAV 
Porcine reproductive and PRRSV 
respiratory syndrome virus 
Porcine hemagglutinating PHEV 
encephalomyelitis virus 
Simian hemorrhagic fever virus SHFV 
II. Target Coronaviruses and Arteriviruses 
The present invention is based on the discovery that effec 
tive inhibition of coronavirus replication can be achieved by 
exposing coronavirus-infected cells to oligomeric analogs (i) 
targeted to the transcriptional regulatory sequence (TRS) 
region of coronavirus RNA and (ii) having physical and phar 
macokinetic features which allow effective interaction 
between the analog and the viral RNA within host cells. In 
one aspect, the analogs can be used in treating a mammalian 
subject infected with the virus. 
The invention targets members of the Coronaviridae and 
Arteriviridae families of the Nidovirales order including, but 
not limited to, the viruses described below. Various physical, 
morphological, and biological characteristics of the genes, 
and members therein, can be found, for example, in (Strauss 
and Strauss 2002), and in one or more of the references cited 
herein. Some of the key biological, pathological and epide 
miological characteristics of representative nidoviruses are 
summarized below. Recent reviews on coronaviruses are 
available (e. g. see (Siddell 1995; Lai and Cavanagh 1997) and 
are incorporated herein in their entirety. 
A. Human Coronaviruses 
Coronaviruses are known to cause approximately 30% of 
common colds in humans. The most studied of these are 
human coronaviruses HCoV-229E and HCoV-OC43. These 
viruses are spread by the respiratory route and, unlike rhi 
noviruses, cause both upper and lower respiratory tract infec 
tions. Lower respiratory tract infections are considered more 
serious clinically. In addition to these viruses, human torovi 
rus (HuTV) causes gastroenteritis and diarrhea in infected 
individuals. 
The SARS-CoV causes a life-threatening form of pneumo 
nia called severe acute respiratory syndrome (SARS). From 
its likely zoonotic origin in Guangdong Province, China in 
November 2002, the SARS-CoV spread rapidly to 29 coun 
tries, infected over 8400 individuals and caused more than 
750 deaths (Peiris, Yuen et al 2003). The rapid transmission 
by aerosols and probably the fecal-oral route coupled with the 
high mortality rate make SARS a global threat for which no 
e?icacious therapy is available. There is evidence that natural 
infection with SARS-CoV occurs in a number of animal 
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species indigenous to China and parts of southeast Asia 
(Guan, Zheng et al 2003). Genome sequences of SARS-CoV 
isolates obtained from a number of index patients have been 
published recently (Marra, Jones et al 2003; Rota, Oberste et 
al 2003). A virus closely related genetically to SARS-CoV 
was isolated from several animals obtained from a market in 
Quangdong Province. Sequencing of the viruses obtained 
from these animals demonstrated that the most signi?cant 
difference between them and SARS-CoV was an additional 
29 base-pair sequence in the animal viruses. The role of 
animals in the transmission of SARS-CoV to humans and 
whether an animal reservoir for the virus exists is the subject 
of active, ongoing research. 
B. Animal Coronaviruses and Arteriviruses 
Coronaviruses and Arteriviruses for many other animals 
are known, including mice chickens, pigs, and cats. Associ 
ated diseases include respiratory disease, gastroenteritis, 
hepatitis, and a syndrome similar to multiple sclerosis of 
humans, among many other illnesses. Mouse hepatitis virus 
(MHV) has been particularly well studied and, along with the 
Arterivirus equine arteritis virus (EAV) has been the proto 
typic molecular model system for the Nidovirales order. 
One animal coronavirus that causes signi?cant animal 
mortality is feline infectious peritonitis virus, the leading 
cause of death in young domestic cats. The feline coronavi 
ruses (FCOV) generally do not cause infections with high 
morbidity but in a small percentage of cases, the virus mutates 
to become more virulent. This virus, feline infectious perito 
nitis virus (FIPV), causes severe disease in young cats. This 
disease is in large part immunopathological and understand 
ing it is a major goal of coronavirus research. The infection 
causes lesions in many organs, most prominently in the liver 
and spleen. The disease is further characterized by dissemi 
nated in?ammation and serositis in the abdominal and tho 
racic cavities. In addition to this “wet” or effusive form, a 
“dry” or noneffusive form of feline infectious peritonitis 
(FIP) also occurs. Both forms are different manifestations of 
the same infection. Despite many studies, the pathogenesis of 
FIP is still not well understood. 
Another serious non-human Nidovirus is porcine repro 
ductive and respiratory syndrome virus (PRRSV), an arterivi 
rus similar to EAV and SHFV. The disease caused by PRRSV 
causes reproductive failure in sows, pre-weaning mortality 
and respiratory tract illness that can have severe conse 
quences, especially in piglets (Allende, Lewis et al. 1999). 
This virus causes signi?cant losses in the pig industry with 
associated economic rami?cations. 
III. Coronavirus and Arterivirus Replication and 
Gene Expression 
Coronaviruses encode an RNA genome that is capped, 
polyadenylated, nonsegmented, infectious, positive-strand, 
approximately 30 kb and considered the largest of all known 
viral RNA genomes. Arteriviruses have a 13 kb genome that 
is very similar in organization and expression strategy to that 
of coronaviruses. The 5' two-thirds of the coronavirus 
genome is occupied by the open reading frame (ORF) 1a and 
ORF lb which encode the replicase proteins of the virus. 
These genes are translated from infecting genomic RNA into 
two polyprotein precursors which produce the viral replica 
tion and transcription functions. Downstream of ORF lb a 
number of genes occur that encode structural and several 
nonstructural, accessory proteins. These genes are expressed 
through a 3'-coterminal nested set of sub genomic mRNAs (s g 
mRNAs) that are synthesized by a process of discontinuous 
transcription. The sg mRNAs represent variable lengths of the 
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3' end of the viral genome, each one provided at its 5' end with 
a sequence identical to the genomic 5' “leader” sequence. The 
mRNAs are each functionally monocistronic (i.e. the proteins 
are translated only from the 5'-most ORF). A schematic that 
illustrates the gene organization and sg mRNAs of SARS 
CoV is shown in FIG. 1 (Thiel, Ivanov et al 2003). 
The control of gene expression by discontinuous transcrip 
tion is novel and unique to a small number of single stranded 
RNA viruses, most notably the Nidovirales order (de Vries, 
Horzinek et al. 1997). FIG. 2A provides a schematic of the 
replication and transcriptional mechanism employed by 
members of the Nidovirales (Pasternak, van den Born et al. 
2001). As with most single stranded, positive-sense RNA 
viruses, the infecting RNA is translated to yield the viral 
encoded RNA polymerase or replicase. The RNA polymerase 
then produces either full length negative-sense RNA, used as 
a template for additional full-length, positive-sense genomic 
RNA synthesis, or a series of negative-sense subgenomic (sg) 
RNAs which serve as templates for synthesis of the comple 
mentary, positive-sense sg mRNAs. This process is termed 
discontinuous transcription (Sawicki and Sawicki 1998). 
Negative-sense sg RNAs are produced by a mechanism in 
which the viral RNA polymerase copies the 3' end of the 
genomic RNA template and completes synthesis by “jump 
ing” to ?nish copying the immediate 5' end. The negative 
sense RNAs are then used to synthesize individual sg 
mRNAs. Each sg mRNA contains the same 5' end sequence 
approximately 70 nucleotides long (approximately 200 
nucleotides in the Arteriviridae) called the leader sequence. 
Coronavirus gene expression is regulated at the level of tran 
scription primarily through the mechanism of discontinuous 
transcription of the negative-sense templates. 
The fusion of the noncontiguous sequences during discon 
tinuous transcription is believed to be achieved through the 
involvement of transcriptional regulatory sequences (TRSs). 
The TRS sequences are short, 6-12 nucleotide regions that are 
found at the 3' end of the leader sequence (leader TRS), and 
upstream of the genes in the 3'-proximal part of the genome 
(body TRSs). The TRSs are homologous and are believed to 
function by a mechanism where the minus-strand body TRS 
“jumps” to the complementary leader TRS on the positive 
sense strand where it “lands” (i.e., the two TRSs hybridize) 
allowing completion of the synthesis of the negative-sense 
leader sequence (i.e., see FIG. 2A) (Pasternak, van den Born 
et al. 2001). 
IV. Antisense Targeting of Nidovirus Transcriptional 
Regulatory Sequences 
The preferred target sequences are those nucleotide 
sequences adjacent and including at least a portion, e.g., at 
least 2-8 bases, of the leader TRS of the positiveiRNA or the 
minus-strand body TRS of Nidovirus RNA. As discussed 
above, the TRSs appear to play a critical role in viral tran 
scription by bringing into close proximity the minus-strand 
body TRS and positive-strand leader TRS in order to com 
plete synthesis of the negative-sense sg RNA templates. FIG. 
2B provides a schematic representation of how and where 
antisense oligomers interfere with the process of discontinu 
ous transcription at these two target sites. 
A variety of Nidovirus genome sequences are available 
from well known sources, such as the NCBI Genbank data 
bases. Alternatively, a person skilled in the art can ?nd 
sequences for many of the subject viruses in the open litera 
ture, e.g., by searching for references that disclose sequence 
US 8,759,307 B2 
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information on designated viruses. Once a complete or partial 
viral sequence is obtained, the leader TRS sequence of the 
virus is identi?ed. 
GenBank references for exemplary viral nucleic acid 
sequences containing the leader TRS or body TRS in the 
corresponding viral genomes are listed in Table 2 below. It 
will be appreciated that these sequences are only illustrative 
of other Nidovirus sequences, as may be available from avail 
able gene-sequence databases or literature or patent 
resources. The sequences below, identi?ed as SEQ ID NOS: 
1-19, are also listed in Table 4 at the end of the speci?cation. 
The bold nucleotides in Table 2 identify the core leader TRS 
or the body minus-strand TRS. 
TABLE 2 
Exemplary TRS Target Sequences 
Leader SEQ 
GenBank TRS ID Target Sequence 
Virus Acc. No.ths. NO.(5‘ to 3W 
FCoV AY204705 109—135 1 cggacaccaacucgaacu 
aaacgaaau 
TGEV AJ271965 78—104 2 cggacaccaacucgaacu 
aaacgaaau 
HCoV—229E AF304460 55—78 3 cuacuuuucucaacuaaa 
cgaaau 
HCoV—OC43 AY391777 51—74 4 gaucuuuuuguaaucuaa 
acuuua 
SARS—CoV AY274119 53—76 5 gaucuguucucuaaacga 
acuuua 
MHV AF029248 50—75 6 guaguuuaaaucuaaucu 
aaacuuua 
SHFV AF180391 188—215 7 gauuugcagacccuccuu 
aaccauguuc 
PRRSV AF046869 168—194 8 cggucucuccaccccuuu 
aaccauguc 
EAV X53459 189—228 9 caucgucgucgaucucua 
ucaacuacccuugcgacu 
augg 
Body 
Minus— SEQTarget Sequence 
GenBank Strand ID (5‘ to 3‘— 
Virus Acc. No.TRS ths. NO.minus strand) 
SARS—CoV AY29131521482— 10 aaaauaaacauguucguu 
21502 uag 
SARS—CoV AY29131525257— 11 acaaauccauaaguucgu 
25277 uua 
SARS—CoV AY29131526109— 12 cgaaugaguacauaaguu 
26129 cgu 
SARS—CoV AY29131526343— 13 auaauaguuaguucguuu 
26363 aga 
SARS—CoV AY29131526913— 14 uuguaauaagaaagcguu 
26933 cgu 
SARS—CoV AY29131527265— 15 gaauaauuuucauguucg 
27285 uuu 
SARS—CoV AY29131527768— 16 gaaguuucauguucguuu 
27788 aga 
SARS—CoV AY29131528103— 17 acauuuuaauuuguucgu 
28123 uua 
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TABLE 2 — cont inued 
SHFV AF18039114699— 18 ucagcacgucgucguggu 
14719 uga 
SHFV AF18039115280— 19 agccauacuuccucaggu 
15300 uaa 
The degree of complementarity between the target and 
targeting sequence is suf?cient to form a stable duplex. The 
region of complementarity of the antisense oligomers with 
the target RNA sequence may be as short as 8-1 1 bases, but is 
preferably 12-15 bases or more, e.g. 12-20 bases, or 12-25 
bases. An antisense oligomer of about 15 bases is generally 
long enough to have a unique complementary sequence in the 
viral genome. In addition, a minimum length of complemen 
tary bases may be required to achieve the requisite binding 
Tm, as discussed below. 
Oligomers as long as 40 bases may be suitable, where at 
least a minimum number ofbases, e.g., 12 bases, are comple 
mentary to the target sequence. In general, however, facili 
tated or active uptake in cells is optimized at oligomer lengths 
less than about 30, preferably less than 25. For PMO oligo 
mers, described further below, an optimum balance of bind 
ing stability and uptake generally occurs at lengths of 15-22 
bases. 
The oligomer may be 100% complementary to the viral 
nucleic acid target sequence, or it may include mismatches, 
e.g., to accommodate variants, as long as a heteroduplex 
formed between the oligomer and viral nucleic acid target 
sequence is suf?ciently stable to withstand the action of cel 
lular nucleases and other modes of degradation which may 
occur in vivo. Oligomer backbones which are less susceptible 
to cleavage by nucleases are discussed below. Mismatches, if 
present, are less destabilizing toward the end regions of the 
hybrid duplex than in the middle. The number of mismatches 
allowed will depend on the length of the oligomer, the per 
centage of G:C base pairs in the duplex, and the position of the 
mismatch(es) in the duplex, according to well understood 
principles of duplex stability. Although such an antisense 
oligomer is not necessarily 100% complementary to the viral 
nucleic acid target sequence, it is effective to stably and 
speci?cally bind to the target sequence, such that a biological 
activity of the nucleic acid target, e. g. discontinous transcrip 
tion, is modulated. 
The stability of the duplex formed between the oligomer 
and the target sequence is a function of the binding Tm and the 
susceptibility of the duplex to cellular enzymatic cleavage. 
The Tm of an antisense compound with respect to comple 
mentary-sequence RNA may be measured by conventional 
methods, such as those described by Hames et al., Nucleic 
Acid Hybridization, IRL Press, 1985, pp. 107-108. Each anti 
sense oligomer should have a binding Tm, with respect to a 
complementary-sequence RNA, of greater than body tem 
perature and preferably greater than 45° C. Tm’s in the range 
60-80° C. or greater are preferred. According to well known 
principles, the Tm of an oligomer compound, with respect to 
a complementary-based RNA hybrid, can be increased by 
increasing the ratio of CG paired bases in the duplex, and/or 
by increasing the length (in base pairs) of the heteroduplex. At 
the same time, for purposes of optimizing cellular uptake, it 
may be advantageous to limit the size of the oligomer. For this 
reason, compounds that show high Tm (50° C. or greater) at a 
length of 15 bases or less are generally preferred over those 
requiring 20+ bases for high Tm values. 















